Atumelnant 120 mg tablets

DRUG2 trials

Sponsors

Crinetics Pharmaceuticals Inc.

Conditions

Classic Congenital Adrenal Hyperplasia• ACTH-Dependent Cushing’s Syndrome. • Pituitary-dependent Cushing´s syndrome.

Phase 2

A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)

Not yet recruitingCTIS2025-522648-42-01

Crinetics Pharmaceuticals Inc.• ACTH-Dependent Cushing’s Syndrome. • Pituitary-dependent Cushing´s syndrome.

Target: 25Updated: 2026-09-29

Phase 3

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants with Classic Congenital Adrenal Hyperplasia

Not yet recruitingCTIS2024-519579-24-00

Crinetics Pharmaceuticals Inc.Classic Congenital Adrenal Hyperplasia

Target: 54Updated: 2026-01-23